February 2017February 2017
New Product - Duavive
Duavive (conjugated estrogens/bazedoxifene) contains conjugated estrogens as a mixture of natural estrogens (of equine origin) and bazedoxifene, a selective estrogen receptor modulator (SERM). The addition of bazedoxifene, acting as an estrogen receptor antagonist in the uterus, greatly reduces the estrogen induced risk of endometrial hyperplasia. Duavive is indicated for treatment of moderate to severe vasomotor symptoms associated with menopause in women with a uterus. Duavive should be used for the shortest duration consistent with treatment goals and risks for the individual woman. Experience in women older than 65 years is limited. Duavive is contraindicated in the following conditions. Known, suspected, or past history of breast cancer; known, past or suspected estrogen dependent malignant tumours (e.g. endometrial cancer); undiagnosed genital bleeding; untreated endometrial hyperplasia; active or past history of venous thromboembolism (e.g. deep venous thrombosis, pulmonary embolism, and retinal vein thrombosis); known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency); active or past history of arterial thromboembolic disease (e.g. myocardial infarction, stroke); acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal; porphyria; pregnancy, women who may become pregnant, and nursing mothers. Duavive is available as modified release tablets containing 0.45 mg conjugated estrogens and 20 mg bazedoxifene in blister packs of 28’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au